TRANSFAL
OFFICIAL TITLE: PROSPECTIVE EVALUATION OF PREDICTIVE/PROGNOSTIC BIOMARKERS FOR PALBOCICLIB AND ENDOCRINE THERAPY IN ER POSITIVE HER2 NEGATIVE ADVANCED METASTATIC BREAST CANCER WITHIN THE PARSIFAL CLINICAL TRIAL.
STUDY DETAILS
THE TRANSFAL PROJECT IS A SUB-STUDY WITHIN THE PARSIFAL CLINICAL TRIAL. THE INITIAL GOAL WILL BE TO ANALYZE THE MOLECULAR TUMOR PROFILE AT THE TIME OF PROGRESSION IN PATIENTS WITH MODERATE SENSITIVITY TO PALBOCICLIB IN COMBINATION WITH FIRST-LINE ENDOCRINE THERAPY. FOR THIS PURPOSE, DIFFERENT MOLECULAR APPROACHES, SUCH AS DIFFERENTIAL PROTEOMICS, IN VIVO PDX MODELS, FISH, DNA SEQUENCING, WILL BE RUN ON AN INITIAL SUBSET OF THE PARSIFAL POPULATION.
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
BREAST
Sub-study
280
52
Spain, France, Italy, UK, Germany, Czech Republic, Russia
Closing
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
SABCS 2019 – DOWNLOAD THE POSTER